| Angela Teresa Powell, MD | |
|
400 Wabash Ave, Akron, OH 44307 | |
| (330) 344-2025 | |
| (330) 344-6418 |
| Full Name | Angela Teresa Powell |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 35 Years |
| Location | 400 Wabash Ave, Akron, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457318784 | NPI | - | NPPES |
| 0137168 | Medicaid | OH | |
| 000000028722 | Other | ANTHEM BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 35067494 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Akron General Medical Center | Akron, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five projects under the Qualifying Therapeutic Discovery Project (QTDP) program.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish eleven Collaborative Research Centres (CRCs) as of 1 January 2013. This was decided by the responsible Grants Committee during its fall session in Bonn.
Today, U.S. scientists committed to finding answers to reducing and eliminating what are known as neglected tropical diseases (NTDs) that plague the world's poorest people in developing countries, urged the FDA to include in its orphan classification the neglected infections of poverty that also affect Americans, and expressed support for stronger relationships with the FDA to ultimately halt these ancient scourges.
OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
› Verified 5 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five projects under the Qualifying Therapeutic Discovery Project (QTDP) program.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish eleven Collaborative Research Centres (CRCs) as of 1 January 2013. This was decided by the responsible Grants Committee during its fall session in Bonn.
Today, U.S. scientists committed to finding answers to reducing and eliminating what are known as neglected tropical diseases (NTDs) that plague the world's poorest people in developing countries, urged the FDA to include in its orphan classification the neglected infections of poverty that also affect Americans, and expressed support for stronger relationships with the FDA to ultimately halt these ancient scourges.
OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
› Verified 5 days ago
| Entity Name | Wooster Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033135009 PECOS PAC ID: 6800708124 Enrollment ID: O20031211000578 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five projects under the Qualifying Therapeutic Discovery Project (QTDP) program.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish eleven Collaborative Research Centres (CRCs) as of 1 January 2013. This was decided by the responsible Grants Committee during its fall session in Bonn.
Today, U.S. scientists committed to finding answers to reducing and eliminating what are known as neglected tropical diseases (NTDs) that plague the world's poorest people in developing countries, urged the FDA to include in its orphan classification the neglected infections of poverty that also affect Americans, and expressed support for stronger relationships with the FDA to ultimately halt these ancient scourges.
OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Angela Teresa Powell, MD 30701 Lorain Rd Ste A, North Olmsted, OH 44070-6325 Ph: (440) 274-5000 | Angela Teresa Powell, MD 400 Wabash Ave, Akron, OH 44307 Ph: (330) 344-2025 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five projects under the Qualifying Therapeutic Discovery Project (QTDP) program.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish eleven Collaborative Research Centres (CRCs) as of 1 January 2013. This was decided by the responsible Grants Committee during its fall session in Bonn.
Today, U.S. scientists committed to finding answers to reducing and eliminating what are known as neglected tropical diseases (NTDs) that plague the world's poorest people in developing countries, urged the FDA to include in its orphan classification the neglected infections of poverty that also affect Americans, and expressed support for stronger relationships with the FDA to ultimately halt these ancient scourges.
OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
› Verified 5 days ago
Dr. Thomas Hlivko, Pathology Medicare: Accepting Medicare Assignments Practice Location: 2215 E Waterloo Rd, Ste 313, Akron, OH 44312 Phone: 330-208-2720 Fax: 330-208-2721 | |
Dr. William Arthur Henthorne, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3786 Fax: 330-375-4874 | |
Eric Douglas Speakman, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 400 Wabash Ave, Akron, OH 44307 Phone: 330-344-2025 Fax: 330-344-6418 | |
Dr. Steven Michael Thompson, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-9678 | |
Dr. Caroline Mitchell Abramovich, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3786 Fax: 330-375-4874 | |
Silvia Deperalta, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3786 Fax: 330-375-4874 | |
Dimitris P Agamanolis, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-8572 Fax: 330-543-3226 |